中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
16期
80-83
,共4页
孟鲁司特钠%毛细支气管炎%儿童
孟魯司特鈉%毛細支氣管炎%兒童
맹로사특납%모세지기관염%인동
Montelukast Sodium%Bronchiolitis%Children
目的：研究孟鲁司特钠治疗儿童毛细支气管炎的临床效果。方法选择2013年9月~2014年3月在房山区良乡医院住院的毛细支气管炎患儿94例，按照给药方法不同分为观察组(n=49)和对照组(n=45)两组。对照组给予常规治疗方法，观察组在对照组的基础上加用孟鲁司特钠片口服。观察比较两组患儿临床疗效、症状消失时间以及不良反应。结果治疗后两组患儿的临床疗效均有明显改善，观察组的总有效率(93.88%)显著高于对照组(82.22%)(P<0.05)。治疗后，观察组嗜酸粒细胞阳离子蛋白(ECP)水平[(9.02±2.37)μg/L]明显高于对照组[(5.17±1.09)μg/L]，差异有统计学意义(P <0.05)；与治疗前相比，治疗后观察组和对照组患儿白介素8(IL-8)水平[(44.68±11.23)μg/L比(31.19±9.28)μg/L，(50.27±13.30)μg/L比(28.54±7.37)μg/L]均明显下降(P<0.05)，但组间比较差异均无统计学意义(P>0.05)。治疗后观察组患儿咳嗽、喘憋、呼吸困难、肺部哮鸣音消失时间以及住院天数[(5.14±1.16)、(4.28±1.31)、(3.66±1.09)、(4.31±1.47)、(7.85±2.03)d]均显著少于对照组[(7.25±1.83)、(6.09±1.50)、(5.03±1.33)、(6.67±1.72)、(11.67±2.53)d]，差异均有统计学意义(均P<0.05)；两组患儿在治疗期间没有发生明显的不良反应。结论孟鲁司特钠口服治疗小儿毛细支气管炎效果显著，且未见不良反应，值得临床推广和使用。
目的：研究孟魯司特鈉治療兒童毛細支氣管炎的臨床效果。方法選擇2013年9月~2014年3月在房山區良鄉醫院住院的毛細支氣管炎患兒94例，按照給藥方法不同分為觀察組(n=49)和對照組(n=45)兩組。對照組給予常規治療方法，觀察組在對照組的基礎上加用孟魯司特鈉片口服。觀察比較兩組患兒臨床療效、癥狀消失時間以及不良反應。結果治療後兩組患兒的臨床療效均有明顯改善，觀察組的總有效率(93.88%)顯著高于對照組(82.22%)(P<0.05)。治療後，觀察組嗜痠粒細胞暘離子蛋白(ECP)水平[(9.02±2.37)μg/L]明顯高于對照組[(5.17±1.09)μg/L]，差異有統計學意義(P <0.05)；與治療前相比，治療後觀察組和對照組患兒白介素8(IL-8)水平[(44.68±11.23)μg/L比(31.19±9.28)μg/L，(50.27±13.30)μg/L比(28.54±7.37)μg/L]均明顯下降(P<0.05)，但組間比較差異均無統計學意義(P>0.05)。治療後觀察組患兒咳嗽、喘憋、呼吸睏難、肺部哮鳴音消失時間以及住院天數[(5.14±1.16)、(4.28±1.31)、(3.66±1.09)、(4.31±1.47)、(7.85±2.03)d]均顯著少于對照組[(7.25±1.83)、(6.09±1.50)、(5.03±1.33)、(6.67±1.72)、(11.67±2.53)d]，差異均有統計學意義(均P<0.05)；兩組患兒在治療期間沒有髮生明顯的不良反應。結論孟魯司特鈉口服治療小兒毛細支氣管炎效果顯著，且未見不良反應，值得臨床推廣和使用。
목적：연구맹로사특납치료인동모세지기관염적림상효과。방법선택2013년9월~2014년3월재방산구량향의원주원적모세지기관염환인94례，안조급약방법불동분위관찰조(n=49)화대조조(n=45)량조。대조조급여상규치료방법，관찰조재대조조적기출상가용맹로사특납편구복。관찰비교량조환인림상료효、증상소실시간이급불량반응。결과치료후량조환인적림상료효균유명현개선，관찰조적총유효솔(93.88%)현저고우대조조(82.22%)(P<0.05)。치료후，관찰조기산립세포양리자단백(ECP)수평[(9.02±2.37)μg/L]명현고우대조조[(5.17±1.09)μg/L]，차이유통계학의의(P <0.05)；여치료전상비，치료후관찰조화대조조환인백개소8(IL-8)수평[(44.68±11.23)μg/L비(31.19±9.28)μg/L，(50.27±13.30)μg/L비(28.54±7.37)μg/L]균명현하강(P<0.05)，단조간비교차이균무통계학의의(P>0.05)。치료후관찰조환인해수、천별、호흡곤난、폐부효명음소실시간이급주원천수[(5.14±1.16)、(4.28±1.31)、(3.66±1.09)、(4.31±1.47)、(7.85±2.03)d]균현저소우대조조[(7.25±1.83)、(6.09±1.50)、(5.03±1.33)、(6.67±1.72)、(11.67±2.53)d]，차이균유통계학의의(균P<0.05)；량조환인재치료기간몰유발생명현적불량반응。결론맹로사특납구복치료소인모세지기관염효과현저，차미견불량반응，치득림상추엄화사용。
Objective To study the effect of Montelukast Sodium in treatment of children with bronchiolitis. Methods A total of 94 cases of children with bronchiolitis in Liangxiang Hospital in Fangshan District of Beijing City from September 2013 to March 2014 were selected and divided into observation group (n=49) and control group (n=45), ac-cording to different therapeutic schemes. And the control group was given the general methods of treatment, and the observation group was based on the same treatment plus Montelukast Sodium Tablets. The clinical effect, symptoms dis-appear time and the incidence of adverse reactions were observed and compared between the two groups. Results The clinical effect between the two groups improved significantly after treatment, the total effective rate in the observation group (93.88%) was higher than that in the control group (82.22%) (P< 0.05). ECP levels in the observation group [(9.02±2.37)μg/L] was higher than that in the control group [(5.17±1.09) μg/L] (P<0.05);IL-8 levels between the two groups after treatment [(44.68±11.23)μg/L vs (31.19±9.28) μg/L, (50.27±13.30) μg/L vs (28.54±7.37) μg/L] were lower than those before the treatment (P< 0.05), but there was no significant difference in two groups after treatment (P>0.05). The symptoms disappear time in the observation group [(5.14±1.16), (4.28±1.31), (3.66±1.09), (4.31±1.47), (7.85±2.03) d] were less than those in control group [(7.25±1.83), (6.09±1.50), (5.03±1.33), (6.67±1.72), (11.67±2.53) d] after treatment (P<0.05). There were no obvious adverse reactions between the two groups during the treatment. Conclu-sion The curative effect of Montelukast Sodium Tablets orally in treating capillary bronchitis is significant, with less ad-verse reactions, which is worthy of clinical promotion and application.
